UPDATE; 07-26-2020
$CAPR reading lonza group ag stuff !!!!![global contract manufacturer]
I am going to say with 100% confidence that the Lonza group AG is the same company she mentioned.
She described them as a global contract manufacturer and if you look at there site,
they are definitely global and provide services to expedite manufacturing.
From the Lonza site under pharma:
[-chart]investorshub.advfn.com/uimage/uploads/2020/7/25/[lfqtlonza.JPG[/chart]
https://pharma.lonza.com/ On the same website but a different page:
[-chart]investorshub.advfn.com/uimage/uploads/2020/7/25/zpclolonza_2.JPG[/chart]
https://www.lonza.com/ UPDATE FROM CEO LINDA 06-23-2020
$CAPR The Big Biz Show Interview Segment 1,CEO INTERVIEW !!!!!LINDA,10YRS. IN DA MAKING !!!!! https://www.youtube.com/watch?v=iHGb9v6fGz0 $CAPR THANK YOU, CEO LINDA INTERVIEW ON TARGET,The Big Biz Show Interview Segment 2 Unlisted 269 views•Jun 23, 2020 https://www.youtube.com/watch?v=qhFxmOGLrCk&feature=youtu.be[/tag]$CAPR reading lonza group ag stuff !!!!![global contract manufacturer]
CAPR HOPE 2 Top Line 12 month Data Call, hosted by Capricor Therapeutics 214 views•May 15, 2020 https://www.youtube.com/watch?v=v_R7U4QpIs8 $CAPR COVID-19 Get the latest information from the CDC about COVID-19.
#COVID19 #CAP1002 #CardiacCellTherapy
Capricor's CAP-1002 - COVID-19 Survival of Critical Patients
649 views•May 24, 2020
https://www.youtube.com/watch?v=mpn34Er0lzA UPDATE FOR RECOVERING NICK CORDERO 06-21-2020
$CAPR strong statement by Amanda Koots wife of TV Star husband Nick Cordero using Capricor Covid-19 treatment drug, she has 338k Instagram followers
re;
[-chart]investorshub.advfn.com/uimage/uploads/2020/6/20/erphrCapture.JPG[/chart]
https://twitter.com/FromIhub/status/1274534417004785664 Source:
https://extratv.com/2020/06/05/amanda-kloots-opens-up-about-nick-corderos-new-treatment/ UPDATE FOR RECOVERING $CAPR TREATMENT 06-20-2020
$CAPR NICE FAMILY MAN RECOVERING NICK CORDERO
https://stocktwits.com/symbol/CAPR?utm_campaign=widget&utm_medium=widget&utm_source=finviz.com $CAPR So Amanda just posted a picture of her and Nick's holding hand.
I think it means he is now free from Coronavirus unless doctor shouldn't have allowed her to touch him.
Am I right? Question to doctors on this board.
$CAPR, $2, READING ALL SMILE with update findings today.
$CAPR, #5,IMPORTANT !!!!! CAP-1002 in Severe COVID-19 Disease,COVID-19 will be documented !!!!!
https://www.clinicaltrials.gov/ct2/show/NCT04338347 
[-chart]capricor.com/wp-content/themes/reverie-master/img/clinical-trials-page-feature-img.jpg[/chart]
http://capricor.com/covid-19/ http://capricor.com/clinical-trials/ http://capricor.com/hope2/ http://capricor.com/hope/ http://capricor.com/clinical-trials/allstar/ http://capricor.com/clinical-trials/dynamic/ http://capricor.com/clinical-trials/caduceus/ 06-03-2020 IMPORTANNT UPDATE AND LINK
https://www.clinicaltrials.gov/ct2/show/NCT04338347
| Responsible Party: | Capricor Inc. |
| ClinicalTrials.gov Identifier: | NCT04338347 History of Changes |
| Other Study ID Numbers: | CAP-1002-COVID-19 |
| First Posted: | April 8, 2020 Key Record Dates |
| Last Update Posted: | May 27, 2020 |
| Last Verified: | May 2020 |
$CAPR, IMPORTANT !!!!! CAP-1002 in Severe COVID-19 Disease,COVID-19 will be documented !!!!! https://www.clinicaltrials.gov/ct2/show/NCT04338347 Study Description Go to sections Brief Summary: This randomized, double-blind, placebo-controlled trial will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing. Eligible subjects will be randomized to either CAP-1002 or placebo in a 1:1 ratio. Intravenous administration of CAP-1002 or placebo will occur at the clinical site on Day 1 and Day 7 (± 1 day) for a maximum of 2 doses, based on clinical course. Subjects will complete Screening, a Treatment Phase and a Follow-up Phase. The Treatment Phase is variable based on each subject's clinical status while the subject remains in the hospital and will contain either one or two treatment periods. Baseline safety and efficacy assessments will be conducted prior to the first infusion. Follow-up will be conducted on Day 15 and Day 30 from the first infusion in Treatment Period 1. Subjects will be observed during the index hospitalization and monitored for outcome and safety. Transthoracic echocardiograms will be performed when indicated by clinical or laboratory evidence of cardiac involvement during the index hospitalization. Use of any concomitant medications to treat COVID-19 will be documented. Stopping rules on the subject-level and study-level have been defined to ensure subjects are not exposed to significant risk. Oversight of the trial will be provided by independent Clinical Event Committee (CEC), Data Safety Monitoring Board (DSMB), and Medical Monitor. Condition or disease Intervention/treatment COVID-19 Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells 05-19-2020
Common stock to be outstanding after the offering 16,664,006 shares The number of shares of our Common Stock that will be outstanding after the offering is based on 12,464,006 shares of our Common Stock outstanding as of April 30, 2020, plus 4,200,000 shares of our Common Stock issuable upon the exercise of Warrants that were issued to the selling shareholders in private placements on March 25, 2020 and March 27, 2020, and excludes: Detailed Description:
This randomized, double-blind, placebo-controlled trial will
enroll subjects with a clinical diagnosis of COVID-19 confirmed
by laboratory testing.
Prior to protocol procedures, informed consent will be obtained
from the subject or a legally authorized representative.
Eligible subjects will be randomized to either CAP-1002 or placebo
in a 1:1 ratio.
Intravenous administration of CAP-1002 or placebo will occur at the clinical site on Day 1 and Day 7 (± 1 day) for a maximum of 2 doses, based on clinical course.
Subjects will complete Screening, a Treatment Phase and a Follow-up Phase.
A detailed medical history will be collected,
including the presence of any co-morbidities and risk factors
believed to be associated with COVID-19 outcomes (e.g., age, gender,
diabetes, COPD or respiratory conditions, body mass index, cardiovascular or renal disease) or emergent factors since the
time of infection.
The Treatment Phase is variable based on each subject's clinical
status while the subject remains in the hospital and will contain
either one or two treatment periods.
Baseline safety and efficacy assessments will be conducted prior
to the first infusion.
Follow-up will be conducted on Day 15 and Day 30 from the first infusion in Treatment Period 1.
Follow-up will either be conducted in the inpatient setting or
as a phone follow-up should the subject be discharged.
Subjects will be observed during the index hospitalization and
monitored for outcome and safety with vital signs (heart rate,
blood pressure, respiratory rate, and oxygen saturation), physical examinations, electrocardiograms (ECGs),
clinical laboratory testing (CBC, CMP, BNP, CRP, ESR, cytokine assay,
viral load, troponin I, myoglobin, ferritin, procalcitonin, ABGs,
and lipid panel), chest x-rays, and adverse events.
A blood sample will be collected at the clinical site and sent to
a central laboratory for proteomic assay testing.
Transthoracic echocardiograms will be performed when indicated by clinical or laboratory evidence of cardiac involvement during the
index hospitalization.
Use of any concomitant medications to treat COVID-19 will be documented.
Stopping rules on the subject-level and study-level have been defined
to ensure subjects are not exposed to significant risk.
Oversight of the trial will be provided by independent Clinical Event Committee (CEC),
Data Safety Monitoring Board (DSMB), and Medical Monitor.
$CAPR, #3,IMPORTANT !!!!! CAP-1002 in Severe COVID-19 Disease,COVID-19 will be documented !!!!! https://www.clinicaltrials.gov/ct2/show/NCT04338347 Study Description Go to sections Brief Summary: This randomized, double-blind, placebo-controlled trial will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing. Study Design Go to sections Study Type : Expanded Access Expanded Access Type : Intermediate-size Population, Treatment IND/Protocol Official Title: A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients With Severe COVID-19 Resource links provided by the National Library of Medicine U.S. FDA: Expanded Access (Compassionate Use) U.S. FDA Resources Interventions Go to sections Intervention Details: Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells Extracellular Vesicles (EVs) from Cardiosphere-Derived Cells (CDCs) Eligibility Criteria Go to sections Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Criteria Inclusion Criteria: Male or female subjects at least 18 years of age at time of consent Diagnosis of SARS-CoV-2 infection confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay Compromised respiratory status as defined by the below criteria to maintain arterial oxygen saturation ≥ 92%, where oxygen saturation is assessed by pulse oximetry OR cardiomyopathy due to COVID-19 (defined as a new drop in ejection fraction to ≤ 50% during COVID-19 with no evidence of obstructive artery disease based on medical record review): Patients requiring mechanical invasive intubation, Patients requiring noninvasive positive pressure ventilation, Patients on non-rebreather face masks or high-flow nasal canula (flow ≥ 6 L/min or FiO2 ≥ 40%) Elevation of at least 1 inflammatory biomarker (IL-1, IL-6, IL-10, TNF-a, ferritin, CRP) defined as ≥ 2x the upper limit of the laboratory reference value Written informed consent provided by the subject or legal representative Criteria Inclusion Criteria: Male or female subjects at least 18 years of age at time of consent Diagnosis of SARS-CoV-2 infection confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay Compromised respiratory status as defined by the below criteria to maintain arterial oxygen saturation ≥ 92%, where oxygen saturation is assessed by pulse oximetry OR cardiomyopathy due to COVID-19 (defined as a new drop in ejection fraction to ≤ 50% during COVID-19 with no evidence of obstructive artery disease based on medical record review): Patients requiring mechanical invasive intubation, Patients requiring noninvasive positive pressure ventilation, Patients on non-rebreather face masks or high-flow nasal canula (flow ≥ 6 L/min or FiO2 ≥ 40%) Elevation of at least 1 inflammatory biomarker (IL-1, IL-6, IL-10, TNF-a, ferritin, CRP) defined as ≥ 2x the upper limit of the laboratory reference value Written informed consent provided by the subject or legal representative Exclusion Criteria: Currently receiving extracorporeal membrane oxygenation (ECMO) or high frequency oscillatory ventilation (HFOV) Patients with established positive bacterial blood cultures prior to enrollment or suspicion of superimposed bacterial pneumonia Patients with untreated HIV infection Creatinine clearance less than 30 ml/minute LFTs > 5x normal Current or history (within the previous 5 years) of systemic autoimmune or connective tissue disease Known allergy or hypersensitivity to any of the investigational product constituents such as dimethyl sulfoxide (DMSO) or bovine proteins Treatment with a cell therapy product within 12 months prior to randomization Pregnant or breastfeeding at screening $CAPR, #5,IMPORTANT !!!!! CAP-1002 in Severe COVID-19 Disease,COVID-19 will be documented !!!!! https://www.clinicaltrials.gov/ct2/show/NCT04338347 Study Description Go to sections Brief Summary: This randomized, double-blind, placebo-controlled trial will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing. Contacts and Locations Go to sections Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04338347 Contacts Contact: Siegfried Rogy, PhD 310-358-3200 clinicalresearch@capricor.com Contact: Larry Larscheid, BS 310-358-3200 clinicalresearch@capricor.com Locations United States, California Cedars-Sinai Medical Center Available Los Angeles, California, United States, 90048 Contact: Mitch Gheoghiu, MD 310-423-6152 Mitch.Gheorghiu@cshs.org Contact: Khaled Alsabaawi 310-423-6226 Khaled.Alsabaawi@cshs.org Sub-Investigator: Tarun Chakravarty, MD Sponsors and Collaborators Capricor Inc. Investigators Principal Investigator: Raj Makkar, MD Cedars-Sinai Medical Center, Los Angeles, CA 90048 More Information Go to sections Responsible Party: Capricor Inc. ClinicalTrials.gov Identifier: NCT04338347 History of Changes Other Study ID Numbers: CAP-1002-COVID-19 First Posted: April 8, 2020 Key Record Dates Last Update Posted: May 27, 2020 Last Verified: May 2020 
Capricor's KOL Call with Dr. Gould from Johns Hopkins "Why Exosomes are Uniquely Suited for Vaccine" https://www.youtube.com/watch?v=zywWw9xS7d8&feature=youtu.be 04-29-2020;
big time play now,huge reporting; U.S. FDA Approves Company’s Expanded [04-29-2020] Access Protocol to Treat Additional Patients https://finance.yahoo.com/news/capricor-data-reports-100-percent-131510422.html LOS ANGELES, April 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today new data reporting 100 percent survival in critical COVID-19 patients who were treated with Capricor’s lead asset, off-the-shelf (“allogeneic”) cardiac cell therapy CAP-1002, at Cedars-Sinai Medical Center as part of six compassionate care cases. Over the course of one month, six critically ill COVID-19 patients, all suffering from acute respiratory distress syndrome (ARDS) and five of whom were on mechanical ventilatory support, were safely treated with CAP-1002. Of the six patients treated, four of them have been discharged. Following a review of the available data, the U.S. Food and Drug Administration (FDA) approved the Company’s expanded access protocol to treat up to 20 additional COVID-19 patients. There is also a randomized, placebo-controlled trial planned to treat patients with moderate and severe disease which is intended to be funded by non-equity capital. In the compassionate care cases, five male patients and one female patient (between ages 19 and 75) suffering from COVID-19 received IV infusions of 150 million allogeneic cardiosphere-derived cells (CAP-1002). Of the five patients on ventilator support, four patients no longer required ventilator support within just one to four days following the infusion. The fifth patient remains on mechanical ventilation and the sixth patient is receiving supplemental oxygen and is currently clinically stable. Additionally, laboratory biomarkers correlated with poor outcomes were measured in all patients. Following infusion, several patients showed improvements in biomarkers, such as ferritin, absolute lymphocyte counts and CRP. No adverse events related to the administration of CAP-1002 were observed. This data has been submitted for publication. CAP-1002 demonstrates immunomodulatory properties. Multiple published peer-reviewed studies of CDCs have demonstrated favorable modulation of various inflammatory cytokines and regulation of the immune response. The current understanding of COVID-19’s later stages are thought to be due to overstimulation of the immune system, which triggers a cytokine storm in which the body is overwhelmed with pro-inflammatory molecules. This immune response may become excessive and pathologic, inducing pneumonia, organ failure and death. Therefore, it can be the body's overreaction to COVID-19, rather than the virus itself, that delivers the fatal blow. "As the global medical community continues to come together in its battle against COVID-19, the results of our initial compassionate care cases are extremely promising and what we had anticipated. We look forward to continuing to treat additional patients under our recently approved expanded access program Investigational New Drug application,” said Dr. Linda Marbán, Ph.D., CEO, Capricor. “CAP-1002 is an easy-to-deliver intravenous therapy that has been administered successfully to over 150 patients to date. Given its novel mechanism of action, it could be a potential game-changer in helping countless COVID-19 patients.” Capricor is also in late-stage clinical development of CAP-1002 for Duchenne muscular dystrophy (DMD). In DMD, the lack of dystrophin produces abnormal inflammatory responses, which are responsible for much of the damage to skeletal and cardiac muscle. The Company has previously announced that top-line results of HOPE-2, a randomized, placebo-controlled study, will be released by mid-May 2020. About Capricor Therapeutics Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment and prevention of diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. For more information, visit http:www.capricor.com and follow the Company on Facebook, Instagram and Twitter. About CAP-1002 CAP-1002 consists of allogeneic “off-the-shelf” cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has been shown in pre-clinical and clinical studies to exert potent immunomodulatory activity. It is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. CDCs have been the subject of over 100 peer-reviewed scientific publications and administered to approximately 150 human subjects across several clinical trials. Cautionary Note Regarding Forward-Looking Statements Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements. CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation. For more information, please contact: Media Contact: Caitlin Kasunich KCSA Strategic Communications ckasunich@kcsa.com 212.896.1241 Investor Contact: Joyce Allaire LifeSci Advisors, LLC jallaire@lifesciadvisors.com 617.435.6602 Company Contact: AJ Bergmann, Chief Financial Officer abergmann@capricor.com 310.358.3200 04-08-2020
Afternoon Delight ????? 'Capricor Therapeutics, Inc. (CAPR)'go'ins to find my baby.
sky rockets in sight.
Afternoon Delight w/ Lyrics
https://www.youtube.com/watch?v=2Ws0VfqkhFc https://www.youtube.com/watch?v=2Ws0VfqkhFc&list=RD2Ws0VfqkhFc&start_radio=1&t=65 Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery,
development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
Capricorâ??s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for
the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies
investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free,
exosome-based candidate, to treat a variety of disorders. For more information,
please visit http://www.capricor.com. 
CAPRICOR THERAPEUTICS, INC.
8840 Wilshire Blvd.
2nd Floor
Beverly Hills, CA 90211
http://capricor.com/product-pipeline/
https://coronavirus.jhu.edu/map.html 
https://www.otcmarkets.com/stock/CAPR/overview https://www.otcmarkets.com/stock/CAPR/quote https://www.otcmarkets.com/stock/CAPR/quote https://www.otcmarkets.com/stock/CAPR/security Share Structure
Market Cap 
10,512,037
04/07/2020
Authorized Shares
Not Available
Outstanding Shares
8,908,506
03/27/2020
Unrestricted
Not Available
Held at DTC
Not Available
Par Value
No Par Value
https://www.otcmarkets.com/stock/CAPR/news https://www.otcmarkets.com/stock/CAPR/disclosure 
[-chart]finviz.com/chart.ashx?t=CAPR&ty=c&ta=1&p=d&s=l[/chart]
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.